Last reviewed 2026-04-20 · How we verify

Ruhmal (CARSALAM)

Phase 2 active Small molecule

Ruhmal (generic name: CARSALAM) is a carsalam drug. It is currently in Phase 2 development.

Ruhmal works by interacting with a specific molecular target to produce a therapeutic effect.

Ruhmal (CARSALAM) is a small molecule drug in the carsalam class, but specific details about its target, indications, and commercial status are unknown. Its mechanism of action and pharmacokinetic properties are also not well-documented. As a result, it is difficult to provide a comprehensive summary of Ruhmal's characteristics and clinical use. Further research is needed to determine its potential therapeutic applications and safety profile. Unfortunately, without more information, it is challenging to assess Ruhmal's current status in the pharmaceutical market.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CARSALAM
Drug class	carsalam
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and Ruhmal has a key that fits into those locks. When Ruhmal binds to its target, it helps to regulate the activity of the cells, which can lead to various therapeutic benefits. This process is a simplified representation of how Ruhmal is thought to work, but the actual mechanism is likely more complex and not fully understood.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Ruhmal CI brief — competitive landscape report
Ruhmal updates RSS · CI watch RSS

Frequently asked questions about Ruhmal

What is Ruhmal?

Ruhmal (CARSALAM) is a carsalam drug.

How does Ruhmal work?

Ruhmal works by interacting with a specific molecular target to produce a therapeutic effect.

What is the generic name of Ruhmal?

CARSALAM is the generic (nonproprietary) name of Ruhmal.

What drug class is Ruhmal in?

Ruhmal belongs to the carsalam class. See all carsalam drugs at /class/carsalam.

What development phase is Ruhmal in?

Ruhmal is in Phase 2.

Drug class: All carsalam drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing